Tybourne Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.71M | Buy |
1,478,152
+516,666
| +54% | +$599K | 4.96% | 6 |
|
|
2025
Q1 | $1.53M | Hold |
961,486
| – | – | 6.49% | 5 |
|
|
2024
Q4 | $2.91M | Hold |
961,486
| – | – | 0.73% | 26 |
|
|
2024
Q3 | $3.54M | Hold |
961,486
| – | – | 0.99% | 14 |
|
|
2024
Q2 | $3.93M | Hold |
961,486
| – | – | 0.8% | 15 |
|
|
2024
Q1 | $15.2M | Hold |
961,486
| – | – | 2.59% | 15 |
|
|
2023
Q4 | $14.6M | Hold |
961,486
| – | – | 2.17% | 18 |
|
|
2023
Q3 | $19.3M | Hold |
961,486
| – | – | 2.69% | 16 |
|
|
2023
Q2 | $27.1M | Sell |
961,486
-670,803
| -41% | -$18.9M | 2.93% | 16 |
|
|
2023
Q1 | $28.1M | Sell |
1,632,289
-599,138
| -27% | -$10.3M | 2.83% | 16 |
|
|
2022
Q4 | $44.9M | Sell |
2,231,427
-70,344
| -3% | -$1.42M | 4.48% | 10 |
|
|
2022
Q3 | $49.9M | Sell |
2,301,771
-124,324
| -5% | -$2.69M | 4.79% | 9 |
|
|
2022
Q2 | $68.2M | Hold |
2,426,095
| – | – | 4.92% | 7 |
|
|
2022
Q1 | $112M | Sell |
2,426,095
-202,314
| -8% | -$9.33M | 6.63% | 3 |
|
|
2021
Q4 | $221M | Sell |
2,628,409
-36,000
| -1% | -$3.03M | 6.56% | 5 |
|
|
2021
Q3 | $178M | Hold |
2,664,409
| – | – | 4.47% | 14 |
|
|
2021
Q2 | $142M | Hold |
2,664,409
| – | – | 2.98% | 17 |
|
|
2021
Q1 | $116M | Hold |
2,664,409
| – | – | 2.54% | 19 |
|
|
2020
Q4 | $138M | Hold |
2,664,409
| – | – | 2.88% | 17 |
|
|
2020
Q3 | $87.1M | Hold |
2,664,409
| – | – | 2.15% | 20 |
|
|
2020
Q2 | $128M | Buy |
+2,664,409
| New | +$128M | 3.89% | 15 |
|